Michael Dickinson - Concepedia

Author

Michael Dickinson

Also Known As

Adrian Minson, DICKINSON, MICHAEL, Dickinson, Mike, M Dickinson, M. Dickinson, M. J Dickinson, M. J. Dickinson, M.J. Dickinson, Michael Dickinson, Michael J Dickinson

464

Publications

10.5K

Citations

H-Index

121

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne The Royal Melbourne Hospital Roche (Switzerland)Roche (United Kingdom)

About

Michael Dickinson is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	27	2.1K
2	Health Sciences	11	12	334
3	Business	3	3	255
4	Engineering	3	3	125
5	Management	3	3	183

Michael Dickinson

116

Publications

Citations

H-Index

Page 1

	Year	Citations
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma Frederick L. Locke, David B. Miklos, Caron A. Jacobson, New England Journal of Medicine	2021	1.4K
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser, New England Journal of Medicine	2022	605
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, The Lancet Oncology Lymphoid NeoplasiaOncologyMalignant Blood DisorderRefractory Follicular LymphomaDermatology	2020	556
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial Nathan Fowler, Michael Dickinson, Martin Dreyling, Nature Medicine Lymphoid NeoplasiaHematologyImmunologyPathologyElara Trial	2021	492
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma Michael R. Bishop, Michael Dickinson, Duncan Purtill, New England Journal of Medicine	2021	491
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia David Ritchie, Paul J. Neeson, Amit Khot, Molecular Therapy	2013	428
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Journal of Clinical Oncology	2021	392
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten, New England Journal of Medicine	2023	359
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Sattva S. Neelapu, Michael Dickinson, Javier Muñoz, Nature Medicine	2022	266
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, The Lancet Oncology Interim AnalysisLymphoid NeoplasiaMedicineImmunologyPathology	2021	245

Page 1